definiens: defined on page 13 of the ADA - SCID License Agreement shall be deleted in its entirety and replaced as follows : “ means ( i ) the clinical trial undertaken by UCL in respect of the ADA SCID Project under the clinical trial reference [ * * * ], ( ii ) the clinical trial to be undertaken by UCL u sing a cryopreserved formulation of autologous ex - vivo lentiviral gene therapy for ADA - deficiency for which ethics and regulatory approval is yet to be obtained ( the cryopreserved trial in ( ii ) is the ) and ( iii ) the compassionate use program ( CUP ) to be undertaken by UCL using a cryop reserved formulation of autologous ex -vivo lentiviral gene therapy for ADA -deficiency ( the ) • [COMPANY] Clinical Trials scope : that the definition of defined on page 13 of the ADA - SCID License Agreement shall be deleted in its entirety and replaced as follows : “ means ( i ) the clinical trial undertaken by [COMPANY] in respect of the ADA SCID Project under the clinical trial referenc e [ * * * ], and ( ii ) the clinical trial undertaken by [COMPANY] us ing a cryopreserved formulation of autologous ex - vivo lentiviral gene therapy for ADA - deficiency und er the clinical trial reference [ * * * ], both ( i ) and ( ii ) performed under the same [ * * * ] ( the cryopreserved trial in ( ii ) is the ) ; ” • Paragraph 5.4.2(iv ): that the phrase in 5.4 . 2(iv ) be replaced with ; • Schedule 1 Part D : that set out on page 64 and 65 of the ADA - SCID License Agreement shall be deleted in its entirety and repl aced and extended as follows : “ For UCLB : [ * * * ] For [COMPANY] : [ * * * ] • The payment obligations under Clause 5.1.4 of the A DA - SCID Licence Agreement shall not apply to UCLB Patient Consents that are the subject of the UCLB C ryo Project ; • The Commercial Obligations under clause 6.2 of the ADA - SCID Licence Agreement shall include the new article 6.2.1 ( d ): • with respect to the rights granted by [COMPANY] specific to the [COMPANY] Cryo Project, abide by ( i ) all the relevant provisions from the California Institute o f Regenerative Medicine ’s Intellectual Property and Revenue Sharing Requirements for Non -Profit and For - Profit Grantees and ( ii ) the provis ions of Title 17, California Code of Regulations, section 100607